Stable Istotope Labelled Reslizumab Biosimilar – Anti-IL5 mAb – Research Grade

Reference: PX-TA1198-SIL-1MG
Product nameStable Istotope Labelled Reslizumab Biosimilar - Anti-IL5 mAb - Research Grade
SourceCAS 241473-69-8
Expression systemMammalian cells
BufferPBS buffer PH7.5
Delivery conditionBlue Ice
Delivery Time3-5 days if in stock; 5-8 weeks if production needed
Storage conditionstore at -80°C
Aliases /SynonymsCDP-835,JES1-39D10,SCH55700
Related ProductsPX-P4558
NoteFor research use only. Not suitable for clinical or therapeutic use.
ClonalityMonoclonal Antibody
LabellingArginine: 13C6,15N4 ; Lysine: 13C6,15N2, >99%
Isotopic Enrichment99%
Stability1 year

General information on Anti-IL5(Homo sapiens) (Reslizumab) Monoclonal Antibody

Reslizumab is a humanized interleukin 5 (IL-5) antagonist monoclonal antibody (IgG4 kappa), produced by recombinant DNA technology in murine non-secretory myeloma 0 (NS0) cells. IL-5 is a pro-inflammatory cytokine responsible for the growth and differentiation, recruitment, activation and survival of eosinophil markers. Elevated levels of eosinophils increase the risk of exacerbation of asthma, including allergic and non-allergic forms of asthma characterized by eosinophilia. By targeting IL-5 and disrupting its signaling pathway, reslizumab aims to inhibit the maturation of eosinophils and promote programmed cell death. Reslizumab is sold as Cinqaero in Europe.


There are no reviews yet.


Be the first to review “Stable Istotope Labelled Reslizumab Biosimilar – Anti-IL5 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Contact us

Send us a message from the form below